Cargando…
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
BACKGROUND: Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of NAFLD confers an additional risk of CVD in patients with T2DM. We investigated...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013458/ https://www.ncbi.nlm.nih.gov/pubmed/35429980 http://dx.doi.org/10.1186/s12933-022-01483-y |
_version_ | 1784687999415484416 |
---|---|
author | Park, Jiyun Kim, Gyuri Kim, Bong-Sung Han, Kyung-Do Kwon, So Yoon Park, So Hee Lee, You-Bin Jin, Sang-Man Kim, Jae Hyeon |
author_facet | Park, Jiyun Kim, Gyuri Kim, Bong-Sung Han, Kyung-Do Kwon, So Yoon Park, So Hee Lee, You-Bin Jin, Sang-Man Kim, Jae Hyeon |
author_sort | Park, Jiyun |
collection | PubMed |
description | BACKGROUND: Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of NAFLD confers an additional risk of CVD in patients with T2DM. We investigated the associations between hepatic steatosis and/or fibrosis and risk of myocardial infarction (MI), stroke, heart failure (HF), and mortality in patients with new-onset T2DM. METHODS: Using the Korean National Health Insurance dataset, we included 139,633 patients diagnosed with new-onset T2DM who underwent a national health screening from January 2009 to December 2012. Hepatic steatosis and advanced hepatic fibrosis were determined using cutoff values for fatty liver index (FLI) and BARD score. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models. RESULTS: During the median follow-up of 7.7 years, there were 3,079 (2.2%) cases of MI, 4,238 (3.0%) cases of ischemic stroke, 4,303 (3.1%) cases of HF, and 8,465 (6.1%) all-cause deaths. Hepatic steatosis defined as FLI ≥ 60 was associated with increased risk for MI (HR [95% CI], 1.28 [1.14–1.44]), stroke (1.41 [1.25–1.56]), HF (1.17 [1.07–1.26]), and mortality (1.41 [1.32–1.51]) after adjusting for well-known risk factors. Compared to the group without steatosis, the group with steatosis and without fibrosis (BARD < 2) and the group with both steatosis and fibrosis (BARD ≥ 2) showed gradual increased risk for MI, stroke, HF, and mortality (all p for trends < 0.001). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI or BARD score were significantly associated with risk of CVD and mortality in new-onset T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01483-y. |
format | Online Article Text |
id | pubmed-9013458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90134582022-04-18 The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study Park, Jiyun Kim, Gyuri Kim, Bong-Sung Han, Kyung-Do Kwon, So Yoon Park, So Hee Lee, You-Bin Jin, Sang-Man Kim, Jae Hyeon Cardiovasc Diabetol Research BACKGROUND: Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of NAFLD confers an additional risk of CVD in patients with T2DM. We investigated the associations between hepatic steatosis and/or fibrosis and risk of myocardial infarction (MI), stroke, heart failure (HF), and mortality in patients with new-onset T2DM. METHODS: Using the Korean National Health Insurance dataset, we included 139,633 patients diagnosed with new-onset T2DM who underwent a national health screening from January 2009 to December 2012. Hepatic steatosis and advanced hepatic fibrosis were determined using cutoff values for fatty liver index (FLI) and BARD score. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models. RESULTS: During the median follow-up of 7.7 years, there were 3,079 (2.2%) cases of MI, 4,238 (3.0%) cases of ischemic stroke, 4,303 (3.1%) cases of HF, and 8,465 (6.1%) all-cause deaths. Hepatic steatosis defined as FLI ≥ 60 was associated with increased risk for MI (HR [95% CI], 1.28 [1.14–1.44]), stroke (1.41 [1.25–1.56]), HF (1.17 [1.07–1.26]), and mortality (1.41 [1.32–1.51]) after adjusting for well-known risk factors. Compared to the group without steatosis, the group with steatosis and without fibrosis (BARD < 2) and the group with both steatosis and fibrosis (BARD ≥ 2) showed gradual increased risk for MI, stroke, HF, and mortality (all p for trends < 0.001). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI or BARD score were significantly associated with risk of CVD and mortality in new-onset T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01483-y. BioMed Central 2022-04-16 /pmc/articles/PMC9013458/ /pubmed/35429980 http://dx.doi.org/10.1186/s12933-022-01483-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Park, Jiyun Kim, Gyuri Kim, Bong-Sung Han, Kyung-Do Kwon, So Yoon Park, So Hee Lee, You-Bin Jin, Sang-Man Kim, Jae Hyeon The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
title | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
title_full | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
title_fullStr | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
title_full_unstemmed | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
title_short | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
title_sort | associations of hepatic steatosis and fibrosis using fatty liver index and bard score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013458/ https://www.ncbi.nlm.nih.gov/pubmed/35429980 http://dx.doi.org/10.1186/s12933-022-01483-y |
work_keys_str_mv | AT parkjiyun theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kimgyuri theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kimbongsung theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT hankyungdo theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kwonsoyoon theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT parksohee theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT leeyoubin theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT jinsangman theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kimjaehyeon theassociationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT parkjiyun associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kimgyuri associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kimbongsung associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT hankyungdo associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kwonsoyoon associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT parksohee associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT leeyoubin associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT jinsangman associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy AT kimjaehyeon associationsofhepaticsteatosisandfibrosisusingfattyliverindexandbardscorewithcardiovascularoutcomesandmortalityinpatientswithnewonsettype2diabetesanationwidecohortstudy |